SAN FRANCISCO (MarketWatch) -- GlaxoSmithKline plc said Monday the supplemental new drug application for its anticoagulant drug candidate Arixtra has been accepted for priority review by the Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results